1. Hehr JD, Schoenbrunner AR, Janis JE. The use of botulinum toxin in pain management: basic science and clinical applications. Plast Reconstr Surg . 2020;145:629e-636e. doi: 10.1097/PRS.0000000000006559
2. Dressler D. Therapeutically relevant features of botulinum toxin drugs. Toxicon . 2020;175:64-68. doi: 10.1016/j.toxicon.2019.12.005
3. Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology . 2015;95:65-69. doi: 10.1159/000370245
4. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A. Am J Clin Dermatol . 2005;6:141-150. https://doi.org/10.2165/00128071-200506030-00001
5. Guzman S, Helander E, Elhassan A. Use of botulinum toxin for chronic pain management. Topics in Pain Management . 2016;31:1-8. doi: 10.1097/01.TPM.0000482997.94909.69
6. Coté TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol . 2005;53:407‐415. doi: 10.1016/j.jaad.2005.06.011
7. Aurora SK, Dodick DW, Turkel CC, et al; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia . 2010;30:793-803. doi: 10.1177/0333102410364676
8. Diener HC, Dodick DW, Aurora SK, et al; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia . 2010Jul;30:804-814. doi: 10.1177/0333102410364677
9. Herd CP, Tomlinson CL, Rick C, et al. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open . 2019;9:e027953. doi: 10.1136/bmjopen-2018-027953
10. Freund B, Rao A. Efficacy of botulinum toxin in tension-type headaches: a systematic review of the literature. Pain Pract . 2019;19:541-551. doi: 10.1111/papr.12773
11. Ward A. Spasticity treatment with botulinum toxins. J Neural Transm . 2008;115:607-616. https://doi.org/10.1007/s00702-007-0833-2
12. Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of upper limb spasticity in children, excluding cerebral palsy [press release]. September 26, 2019. Accessed October 27, 2021. www.businesswire.com/news/home/20190926005480/en/Ipsen-Announces-FDA-Approval-Dysport%C2%AE-abobotulinumtoxinA-Treatment
13. Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J . 1989;65:208-210. doi: 10.1136/pgmj.65.762.208
14. Spiegel LL, Ostrem JL, Bledsoe IO. FDA approvals and consensus guidelines for botulinum toxins in the treatment of dystonia. Toxins (Basel) . 2020;12:332. doi: 10.3390/toxins12050332
15. Castelão M, Marques RE, Duarte GS, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev . 2017;12:CD003633. doi: 10.1002/14651858.CD003633.pub3
16. Contarino MF, Van Den Dool J, Balash Y, et al. Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin. Front Neurol . 2017;8:35. doi: 10.3389/fneur.2017.00035
17. Kumar R. Therapeutic use of botulinum toxin in pain treatment. Neuronal Signal . 2018;2:NS20180058. https://doi.org/10.1042/NS20180058
18. Singh JA. Use of botulinum toxin in musculoskeletal pain. F1000Research. 2013;2:52. https://doi.org/10.12688/f1000research.2-52.v2
19. Blanshan N, Krug H. The use of botulinum toxin for the treatment of chronic joint pain: clinical and experimental evidence. Toxins (Basel) . 2020;12:314. doi: 10.3390/toxins12050314
20. Hsu P-C, Wu W-T, Han D-S, et al. Comparative effectiveness of botulinum toxin injection for chronic shoulder pain: a meta-analysis of randomized controlled trials. Toxins (Basel) . 2020;12:251. doi: 10.3390/toxins12040251
21. Zhai S, Huang B, Yu K. The efficacy and safety of botulinum toxin type A in painful knee osteoarthritis: a systematic review and meta-analysis. J Int Med Res . 2020;48:300060519895868. doi: 10.1177/0300060519895868
22. Isner-Horobeti ME, Dufour SP, Blaes C, et al. Intramuscular pressure before and after botulinum toxin in chronic exertional compartment syndrome of the leg: a preliminary study. Am J Sports Med . 2013;41:2558‐2566. doi: 10.1177/0363546513499183
23. Hutto WM, Schroeder PB, Leggit JC. Botulinum toxin as a novel treatment for chronic exertional compartment syndrome in the US Military. Mil Med . 2019;184:e458‐e461. doi: 10.1093/milmed/usy223
24. Rahman A, Hamid A, Inozemtsev K, et al. Thoracic outlet syndrome treated with injecting botulinum toxin into middle scalene muscle and pectoral muscle interfascial planes: a case report. A A Pract . 2019;12:235‐237. doi: 10.1213/XAA.0000000000000894
25. Finlayson HC, O’Connor RJ, Brasher PMA, et al. Botulinum toxin injection for management of thoracic outlet syndrome: a double-blind, randomized, controlled trial. Pain . 2011;152:2023-2028. doi: 10.1016/j.pain.2011.04.027
26. Donahue DM, Godoy IRB, Gupta R, et al. Sonographically guided botulinum toxin injections in patients with neurogenic thoracic outlet syndrome: correlation with surgical outcomes. Skeletal Radiol . 2020;49:715-722. https://doi.org/10.1007/s00256-019-03331-9
27. Wei J, Zhu X, Yang G, et al. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: a meta‐analysis of randomized controlled trials. Brain Behav . 2019;9:e01409. doi: 10.1002/brb3.1409
28. Samant PD, Kale SY, Ahmed S, et al. Randomized controlled study comparing clinical outcomes after injection botulinum toxin type A versus corticosteroids in chronic plantar fasciitis. Int J Res Orthop . 2018;4:672-675. http://dx.doi.org/10.18203/issn.2455-4510.IntJResOrthop20182744
29. Fry DA. Is botulinum toxin injection effective in reducing pain in patients diagnosed with plantar fasciitis? PCOM Physician Assistant Studies Student Scholarship . 2019;461. https://digitalcommons.pcom.edu/pa_systematic_reviews/461
30. Lin YC, Wu WT, Hsu YC, et al. Comparative effectiveness of botulinum toxin versus non-surgical treatments for treating lateral epicondylitis: a systematic review and meta-analysis. Clin Rehabil . 2018;32:131-145. doi: 10.1177/0269215517702517
31. Ruiz AG, Díaz GV, Fernández BR, et al. Effects of ultrasound-guided administration of botulinum toxin (incobotulinumtoxinA) in patients with lateral epicondylitis. Toxins (Basel) . 2019;11:46. doi: 10.3390/toxins11010046
32. Villa S, Raoul G, Machuron F, et al. Improvement in quality of life after botulinum toxin injection for temporomandibular disorder. J Stomatol Oral Maxillofac Surg . 2019;120:2-6. doi: 10.1016/j.jormas.2018.10.00
33. Fu KY, Che, HM, Sun ZP, et al. Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint. Br J Oral Maxillofac Surg . 2010;48:281-284. doi: 10.1016/j.bjoms.2009.07.014
34. Machado D, Kumar A, Jabbari B. Abobotulinum toxin A in the treatment of chronic low back pain. Toxins (Basel) . 2016;8:374. doi: 10.3390/toxins8120374
35. Cogné M, Petit H, Creuzé A, et al. Are paraspinous intramuscular injections of botulinum toxin a (BoNT-A) efficient in the treatment of chronic low-back pain? A randomised, double-blinded crossover trial. BMC Musculoskelet Disord . 2017;18:454. https://doi.org/10.1186/s12891-017-1816-6
36. Ahmed S, Subramaniam S, Sidhu K, et al. Effect of local anesthetic versus botulinum toxin-A injections for myofascial pain disorders. Clin J Pain . 2019;35:353-367. doi: 10.1097/AJP.0000000000000681
37. Mathias SD, Kuppermann M, Liberman RF, et al. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996;87:321-327. doi: 10.1016/0029-7844(95)00458-0
38. Luo FY, Nasr-Esfahani M, Jarrell J, et al. Botulinum toxin injection for chronic pelvic pain: a systematic review. Acta Obstet Gynecol Scand . 2020;99:1595-1602. https://doi.org/10.1111/aogs.13946
39. Lessard L, Bartow MJ, Lee J, et al. Botulinum toxin A: a novel therapeutic modality for upper extremity chronic regional pain syndrome. Plast Reconstr Surg Glob Open . 2018;6:e1847. doi: 10.1097/GOX.0000000000001847
40. Lee Y, Lee CJ, Choi E, et al. Lumbar sympathetic block with botulinum toxin type A and type B for the complex regional pain syndrome. Toxins (Basel) . 2018;10:164. doi: 10.3390/toxins10040164
41. Kwak H, Koh DJ, Min K. Botulinum toxin treatment for intractable allodynia in a patient with complex regional pain syndrome: a case report. Neurology Asia. 2020;25:215-219.
